Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier

被引:222
作者
Gumbleton, M
Audus, KL
机构
[1] Cardiff Univ, Welsh Sch Pharm, Cardiff CF10 3XF, S Glam, Wales
[2] Univ Kansas, Sch Pharm, Dept Pharmaceut Chem, Lawrence, KS 66047 USA
关键词
blood-brain barrier; in vitro model; cell culture; permeability; brain capillary endothelial cell; transendothelial transport;
D O I
10.1002/jps.1119
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A relatively simple, widely applicable, and robust in vitro method of predicting blood-brain barrier (BBB) permeability to central nervous system-acting drugs is an increasing need. A cell-based model offers the potential to account for transcellular and paracellular drug diffusional processes, metabolism, and active transport processes, as well as nondefined interactions between a drug and cellular material that may impact upon a membrane's overall permeability profile. Any in vitro BBB cell model to be utilized for the transendothelial BBB permeability screening of potential central nervous system drugs must display reproducible solute permeability, and a number of other general criteria including: a restrictive paracellular barrier; a physiologically realistic cell architecture; the functional expression of key transporter mechanisms; and allow ease of culture to meet the technical and time constraints of a screening program. This article reviews the range of in vitro cell-based BBB models available, including the primary/low passage bovine and porcine brain endothelial cultures as well as the spectrum of immortalized brain endothelial cell lines that have been established. The article further discusses the benefits and limitations of exploiting such systems as in vitro BBB permeability screens. (C) 2001 Wiley-Liss, Inc. and the American Pharmaceutical Association.
引用
收藏
页码:1681 / 1698
页数:18
相关论文
共 163 条
  • [31] A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier
    Dehouck, B
    Fenart, L
    Dehouck, MP
    Pierce, A
    Torpier, G
    Cecchelli, R
    [J]. JOURNAL OF CELL BIOLOGY, 1997, 138 (04) : 877 - 889
  • [32] DRUG TRANSFER ACROSS THE BLOOD-BRAIN-BARRIER - CORRELATION BETWEEN INVITRO AND INVIVO MODELS
    DEHOUCK, MP
    JOLLIETRIANT, P
    BREE, F
    FRUCHART, JC
    CECCHELLI, R
    TILLEMENT, JP
    [J]. JOURNAL OF NEUROCHEMISTRY, 1992, 58 (05) : 1790 - 1797
  • [33] Deli M A, 1995, Inflamm Res, V44 Suppl 1, pS56, DOI 10.1007/BF01674394
  • [34] PENETRATION OF SMALL MOLECULAR-WEIGHT SUBSTANCES THROUGH CULTURED BOVINE BRAIN CAPILLARY ENDOTHELIAL-CELL MONOLAYERS - THE EARLY EFFECTS OF CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE
    DELI, MA
    DEHOUCK, MP
    ABRAHAM, CS
    CECCHELLI, R
    JOO, F
    [J]. EXPERIMENTAL PHYSIOLOGY, 1995, 80 (04) : 675 - 678
  • [35] Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells
    Descamps, L
    Dehouck, MP
    Torpier, G
    Cecchelli, R
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1996, 270 (04): : H1149 - H1158
  • [36] HIV protease inhibitor ritonavir:: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
    Drewe, J
    Gutmann, H
    Fricker, G
    Török, M
    Beglinger, C
    Huwyler, J
    [J]. BIOCHEMICAL PHARMACOLOGY, 1999, 57 (10) : 1147 - 1152
  • [37] DURIEUTRAUTMANN O, 1991, IN VITRO CELL DEV B, V27, P771
  • [38] Modulation of P-glycoprotein activity by glial factors and retinoic acid in an immortalized rat brain microvessel endothelial cell line
    ElHafny, B
    Chappey, O
    Piciotti, M
    Debray, M
    Boval, B
    Roux, F
    [J]. NEUROSCIENCE LETTERS, 1997, 236 (02) : 107 - 111
  • [39] Role of P-glycoprotein in colchicine and vinblastine cellular kinetics in an immortalized rat brain microvessel endothelial cell line
    ElHafny, B
    Cano, N
    Piciotti, M
    Regina, A
    Scherrmann, JM
    Roux, F
    [J]. BIOCHEMICAL PHARMACOLOGY, 1997, 53 (11) : 1735 - 1742
  • [40] ElHafny B, 1996, J CELL PHYSIOL, V167, P451, DOI 10.1002/(SICI)1097-4652(199606)167:3<451::AID-JCP9>3.3.CO